1365 related articles for article (PubMed ID: 28979628)
1. Determination
Thuku NW; Shikuku K; Mbugua A
Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis.
Eriksson L; Kristensen J; Olsson K; Bring J; Högman CF
Vox Sang; 1996; 70(2):69-75. PubMed ID: 8801766
[TBL] [Abstract][Full Text] [Related]
3. Transfusion of platelet concentrates--clinical evaluation of two preparations.
Strindberg J; Berlin G
Eur J Haematol; 1996 Oct; 57(4):307-11. PubMed ID: 8982294
[TBL] [Abstract][Full Text] [Related]
4. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
[TBL] [Abstract][Full Text] [Related]
5. Effects of high-yield thrombocytapheresis on the quality of platelet products.
Julmy F; Ammann RA; Mansouri Taleghani B; Fontana S; Hirt A; Leibundgut K
Transfusion; 2008 Mar; 48(3):442-50. PubMed ID: 18067508
[TBL] [Abstract][Full Text] [Related]
6. In-vivo evaluation of random donor platelet concentrates from pooled buffy coats.
Klüter H; Dörges L; Maass E; Wagner T; Bartels H; Kirchner H
Ann Hematol; 1996 Aug; 73(2):85-9. PubMed ID: 8774617
[TBL] [Abstract][Full Text] [Related]
7. Implementation of a new platelet pooling system for platelet concentrates led to a higher corrected count increment after transfusion: a comparative observational study of platelet concentrates before and after implementation.
Dijkstra-Tiekstra MJ; van de Watering LM; Rondeel JM; Slomp J; de Wildt-Eggen J
Transfus Med; 2014 Apr; 24(2):99-104. PubMed ID: 24506143
[TBL] [Abstract][Full Text] [Related]
8. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
[TBL] [Abstract][Full Text] [Related]
9. Quality and safety of platelet apheresis concentrates produced with a new leukocyte reduction system.
Riggert J; Humpe A; Simson G; Köhler M
Vox Sang; 1998; 74(3):182-8. PubMed ID: 9595646
[TBL] [Abstract][Full Text] [Related]
10. Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution.
Davis KB; Slichter SJ; Corash L
Transfusion; 1999 Jun; 39(6):586-92. PubMed ID: 10378838
[TBL] [Abstract][Full Text] [Related]
11. Intravascular and total body platelet equilibrium in healthy volunteers and in thrombocytopenic patients transfused with single donor platelets.
Brubaker DB; Marcus C; Holmes E
Am J Hematol; 1998 Jul; 58(3):165-76. PubMed ID: 9662266
[TBL] [Abstract][Full Text] [Related]
12. Clinical factors influencing corrected count increment.
Shastry S; Chaudhary R
Transfus Apher Sci; 2012 Dec; 47(3):327-30. PubMed ID: 22705296
[TBL] [Abstract][Full Text] [Related]
13. Platelet function testing to assess effectiveness of platelet transfusion therapy.
Salama ME; Raman S; Drew MJ; Abdel-Raheem M; Mahmood MN
Transfus Apher Sci; 2004 Apr; 30(2):93-100. PubMed ID: 15062745
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of transfusion of platelet concentrates obtained by manual pooling or by semiautomated pooling of buffy-coats: a retrospective analysis of count increment, corrected count increment and transfusion interval.
Cid J; Ramiro L; Escoda L; Llorente A
Vox Sang; 2009 Jan; 96(1):29-33. PubMed ID: 19121195
[TBL] [Abstract][Full Text] [Related]
15. Benefit of prestorage leukocyte depletion of single-donor platelet concentrates.
Chalandon Y; Mermillod B; Beris P; Doucet A; Chapuis B; Roux-Lombard P; Dayer JM
Vox Sang; 1999; 76(1):27-37. PubMed ID: 9933851
[TBL] [Abstract][Full Text] [Related]
16. Pretransfusion incubation of apheresis platelets at 37 degrees C improves posttransfusion recovery.
Shanwell A; Wikman A; Ringdén O
Transfusion; 1992 Oct; 32(8):715-8. PubMed ID: 1412678
[TBL] [Abstract][Full Text] [Related]
17. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components.
Eernisse JG; Brand A
Exp Hematol; 1981 Jan; 9(1):77-83. PubMed ID: 7238644
[TBL] [Abstract][Full Text] [Related]
18. WBC-reduced platelet concentrates from pooled buffy coats in additive solution: an evaluation of in vitro and in vivo measures.
van der Meer PF; Pietersz RN; Tiekstra MJ; Huijgens PC; Dekker WJ; Reesink HW
Transfusion; 2001 Jul; 41(7):917-22. PubMed ID: 11452160
[TBL] [Abstract][Full Text] [Related]
19. Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy.
Akkök CA; Brinch L; Lauritzsen GF; Solheim BG; Kjeldsen-Kragh J
Vox Sang; 2007 Jul; 93(1):42-8. PubMed ID: 17547564
[TBL] [Abstract][Full Text] [Related]
20. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components--a randomized trial.
Oksanen K; Kekomäki R; Ruutu T; Koskimies S; Myllylä G
Transfusion; 1991 Sep; 31(7):588-94. PubMed ID: 1891788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
